Vaccination against SARS-CoV-2 in pregnancy during the Omicron wave: the prospective cohort study of the Italian obstetric surveillance system

Decenti, Edoardo Corsi; Salvatore, Michele Antonio; Mandolini, Donatella; Donati, Serena; Alberi, Irene; Camandona, F.; Casucci, Paola; Cetin, Irene; Ciavattini, Andrea; Damiani, Fabrizio; Sebastiano, F. Di; Driul, Lorenza; Droghini, Fiorenza; Giuseppe,; Farsetti, D.; Franchi, Massimo Piergiuseppe; Leo, Livio; Liberati, Marco; Sacchi, Lucia Li; Locci, Mariavittoria; Martini, Claudio; Maso, Gianpaolo; Mecacci, Federico; Meloni, Alessandra; Mignuoli, Anna Domenica; Mondo, Luisa; Morano, Danila; Paradiso, Rocco; Perrone, Enrica; Piccinno, R.; Prefumo, Federico; Ramenghi, Luca A.; Rocca, Morena; Sampaolo, Letizia; Scalchi, Sabrina; Schettini, Sergio Crescenzo Antonio; Simeone, Daniela; Simeone, Serena; Steinkasserer, Martin; Taddeï, F.; Tesorone, Marina; Trojano, Vito; Tronci, Caterina; Veneziano, Micaela; Vimercati, Antonella

doi:10.1016/j.cmi.2023.01.013

Cited by 10 publications

(5 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, with regard to infants, relating to the risk of hospitalization during the first six months of life, maternal COVID-19 vaccination with a second dose during pregnancy was highly effective against delta and moderately effective against omicron [ 70 ]. In a national prospective cohort study from Italy including 2147 women, it was shown that the incidence of moderate or severe COVID-19 during the omicron surge was rare, but was significantly higher in unvaccinated individuals [ 71 ].…”

Section: Discussionmentioning

confidence: 99%

COVID-19 Pharmacotherapy in Pregnancy: A Literature Review of Current Therapeutic Choices

Akinosoglou

Schinas

Rigopoulos

et al. 2023

Viruses

View full text Add to dashboard Cite

The clinical management of COVID-19 in pregnant women, who are considered a vulnerable population, remains uncertain even as the pandemic subsides. SARS-CoV-2 affects pregnant individuals in multiple ways and has been associated with severe maternal morbidity and mortality, as well as neonatal complications. The unique anatomy and physiology of gestation make managing COVID-19 in this population a complex and challenging task, emphasizing the importance of spreading knowledge and expertise in this area. Therapeutic interventions require distinct clinical consideration, taking into account differences in pharmacokinetics, vertical transmission, drug toxicities, and postnatal care. Currently, there is limited data on antiviral and immunomodulating COVID-19 pharmacotherapy in pregnancy. Some medication has been shown to be safe and well tolerated among pregnant women with COVID-19; however, the lack of randomized clinical trials and studies in this patient population is evident. Available vaccines are considered safe and effective, with no evidence of harm to the fetus, embryo development, or short-term postnatal development. Pregnant women should be counseled about the risks of SARS-CoV-2 infection and informed of available ways to protect themselves and their families. Effective treatments for COVID-19 should not be withheld from pregnant individuals, and more research is needed to ensure the best outcomes.

show abstract

Section: Discussionmentioning

confidence: 99%

COVID-19 Pharmacotherapy in Pregnancy: A Literature Review of Current Therapeutic Choices

Akinosoglou

Schinas

Rigopoulos

et al. 2023

Viruses

View full text Add to dashboard Cite

show abstract

“…Protective effect against moderate to severe COVID-19 and some adverse pregnancy outcomes were observed vaccination before or during pregnancy 30,31 . We initially tried to evaluate the effectiveness of vaccine against this wave of pandemic.…”

Section: Limitationsmentioning

confidence: 98%

Intrauterine transmission, pregnant outcomes after infection of SARS-CoV-2 during first or second trimester: a small cohort study during Omicron stage

Zhu,

Jiang,

Cao

et al. 2024

Preprint

View full text Add to dashboard Cite

Background The emergence of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has posed significant public health challenges. Although vaccination provides protection against severe COVID-19, its efficacy against infection and mild symptoms wanes, leaving pregnant women, who are at an increased risk of severe complications, vulnerable. Methods In a prospective study conducted from January 31 to February 28, 2023, 225 women with 239 fetuses underwent chromosomal microarray analysis via amniocentesis. Participants were tested for SARS-CoV-2 RNA to ensure negativity prior to the procedure. Maternal and infection-related data were collected, and amniotic fluid samples were analyzed for SARS-CoV-2 RNA using qRT-PCR. Pregnancy outcomes were assessed through obstetric ultrasound and follow-ups. Results None of the 140 amniotic fluid samples tested positive for SARS-CoV-2 RNA, indicating no intrauterine transmission. There were no significant differences in the rates of premature delivery or birth weight between the groups infected in the first and second trimesters. Conclusion The study found no evidence of vertical transmission or adverse pregnancy outcomes following SARS-CoV-2 infection during the first and second trimesters. The impact of Omicron variant infection during these periods was mild, suggesting that amniocentesis beyond the acute stage of COVID-19 is safe.

show abstract

“…In Italia, fin dall'inizio della pandemia, l'Italian Obstetric Surveillance System (ItOSS https://www.epicentro.iss.it/itoss/) dell'Istituto Superiore di Sanità (ISS) ha avviato uno studio nazionale prospettico populationbased per monitorare le donne in gravidanza con infezione da SARS-CoV-2 ricoverate in ospedale 2 . Oltre 11.000 donne positive sono state arruolate da febbraio 2020 a giugno 2021 e da gennaio a maggio 2022, permettendo di analizzare l'impatto del virus originario, delle varianti Alfa e Omicron sugli esiti di salute materni e perinatali [3][4][5][6][7][8][9] . Lo studio ha confermato che nel periodo dominato dalla variante Omicron la vaccinazione protegge dalle forme gravi di Covid-19 e da esiti materni e perinatali sfavorevoli 9 .…”

Section: Lettere Lettereunclassified

“…Oltre 11.000 donne positive sono state arruolate da febbraio 2020 a giugno 2021 e da gennaio a maggio 2022, permettendo di analizzare l'impatto del virus originario, delle varianti Alfa e Omicron sugli esiti di salute materni e perinatali [3][4][5][6][7][8][9] . Lo studio ha confermato che nel periodo dominato dalla variante Omicron la vaccinazione protegge dalle forme gravi di Covid-19 e da esiti materni e perinatali sfavorevoli 9 . I risultati degli studi INTERCOVID-2022 e ItOSS sull'impatto della variante Omicron descrivono una fase avanzata di un percorso complesso che a livello globale ha visto, ancora una volta, escludere le donne in gravidanza dai trial valutativi di nuovi farmaci e vaccini a causa del pensiero dominante che vede nella loro "esclusione" la migliore forma di "protezione" 10,11 .…”

Section: Lettere Lettereunclassified

“…A seguito della pubblicazione di maggiori prove su sicurezza ed efficacia dei vaccini in gravidanza 13 , la raccomandazione veniva estesa a tutte le donne al secondo e terzo trimestre e solo nell'agosto 2022 a tutte le epoche gestazionali 12 . Pur disponendo di evidenze robuste a sostegno dei benefici per mamme e neonati della vaccinazione contro il Covid in gravidanza 1,8,9,14 , oggi persiste un'esitazione verosimilmente associata alla scelta di escludere le donne in gravidanza dai trial clinici 13,14 . La comunicazione difficile e talora contraddittoria, inoltre, non ha migliorato il già fragile rapporto fiduciale tra professionisti sanitari e cittadini.…”

Section: Lettere Lettereunclassified

See 1 more Smart Citation

Lettere

Donati

2023

Medico E Bambino

Self Cite

View full text Add to dashboard Cite

show abstract

Vaccination against SARS-CoV-2 in pregnancy during the Omicron wave: the prospective cohort study of the Italian obstetric surveillance system

Cited by 10 publications

References 26 publications

COVID-19 Pharmacotherapy in Pregnancy: A Literature Review of Current Therapeutic Choices

COVID-19 Pharmacotherapy in Pregnancy: A Literature Review of Current Therapeutic Choices

Intrauterine transmission, pregnant outcomes after infection of SARS-CoV-2 during first or second trimester: a small cohort study during Omicron stage

Lettere

Contact Info

Product

Resources

About